Ovarian cancer: A brief historical overview of intraperitoneal trials

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1429-1434

  Kwa, Maryann ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETER COMPLICATION; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DOSE DENSIFICATION; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; INTRAPERITONEAL CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); FEMALE; HISTORY; INTRAPERITONEAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HISTORY, 20TH CENTURY; HUMANS; INJECTIONS, INTRAPERITONEAL; OVARIAN NEOPLASMS;

EID: 84898669955     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3219-8     Document Type: Article

References (32)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-200. (Pubitemid 46606249)
3. Piccart MJ, Bertelssen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708. (Pubitemid 30365530)
4. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel in patient with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-15. (Pubitemid 30036343)
5. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet. 2002;360(9332):505-15. (Pubitemid 35232102)
6. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-25.
7. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomized controlled trial. Lancet. 2009;374(9698):1331- 8.
8. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1-9.
9. Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845-51. (Pubitemid 13240565)
10. Casper ES, Kelsen DP, Alcock NW, et al. IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep. 1983;67:235-8. (Pubitemid 13121459)
11. Colombo N, Speyer JL, Green M, et al. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol. 1989;23:323-8. (Pubitemid 19087694)
12. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5:1607-12. (Pubitemid 18010139)
13. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: A review, with focus on practical aspects of treatment. J Clin Oncol. 2006;24:988-94. (Pubitemid 46638854)
14. Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer. 2009;18(Suppl 1):20-5. (Pubitemid 351389048)
15. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-5. (Pubitemid 26428219)
16. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-7. (Pubitemid 32176274)
17. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
18. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;11:CD005340.
19. National Cancer Institute. NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. 2006. http://www.cancer.gov/ newscenter/pressreleases/2006/ipchemotherapyrelease.
20. Trimble EL, Alvarez RD. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol. 2006;103:S18-9. (Pubitemid 44633412)
21. Echarri Gonzalez MJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park). 2011; 25:156-65.
22. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23:431-42. (Pubitemid 47272773)
23. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-60. (Pubitemid 10140145)
24. Ruffian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;94:316-24. (Pubitemid 44330855)
25. Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-25.
26. Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20:61-9.
27. Deraco M, Kusamura S, Virzi S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutionalized phase II trial. Gynecol Oncol. 2011;122:215-20.
28. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of the National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32:671-5. (Pubitemid 44063998)
29. Helm CW, Randall-Whitis L, Martin RS III, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007;105:90-6. (Pubitemid 46441446)
30. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813-20. (Pubitemid 47283201)
31. Fagotti A, Constantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatments and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221-5.
32. Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21(4): 645-63.